Confidentiality protections versus collaborative care in the treatment of substance use disorders by Jennifer K Manuel et al.
Manuel et al. Addiction Science & Clinical Practice 2013, 8:13
http://www.ascpjournal.org/content/8/1/13REVIEW Open AccessConfidentiality protections versus collaborative
care in the treatment of substance use disorders
Jennifer K Manuel1*, Howard Newville1,2, Sandra E Larios1 and James L Sorensen1Abstract
Practitioners in federally-assisted substance use disorder (SUD) treatment programs are faced with increasingly
complex decisions when addressing patient confidentiality issues. Recent policy changes, intended to make
treatment more available and accessible, are having an impact on delivery of SUD treatment in the United States.
The addition of electronic health records provides opportunity for more rapid and comprehensive communication
between patients’ primary and SUD care providers while promoting a collaborative care environment. This shift
toward collaborative care is complicated by the special protections that SUD documentation receives in SUD
treatment programs, which vary depending on what care is provided and the setting where the patient is treated.
This article explores the special protections for substance abuse documentation, discrepancies in treatment
documentation, ways to deal with these issues in clinical practice, and the need for more knowledge about how to
harmonize treatment in the SUD and primary care systems.
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Increasingly, substance use assessment and treatment
is occurring in health care settings such as primary
care clinics, emergency departments, and trauma
units. Furthermore, many health care settings have
adopted or plan to adopt the use of electronic health
records (EHRs), a change that can facilitate the integration
of substance use disorder (SUD) treatment with other
forms of health care. Thus, the landscape of SUD treatment
has shifted in recent years. At the same time, current
regulations for SUD treatment confidentiality have
not been updated, despite the number of changes in
how and where SUD is delivered. In this paper, the
authors provide a summary of recent legislative and
policy changes, the reasons for confidentiality protections,
review the degree that substance abuse treatment
documentation is protected in different environments, and
suggest several directions for maintaining confidentiality
while promoting coordination of care.* Correspondence: jknappmanuel@gmail.com
1University of California, San Francisco at San Francisco General Hospital,
Bldg 20, Ste. 2100, Rm 2127 1001 Potrero Avenue, San Francisco, CA 94110,
USA
Full list of author information is available at the end of the article
© 2013 Manuel et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe advance of electronic health records systems
The American Recovery and Reinvestment Act of 2009
(ARRA), also known as the “economic stimulus package”,
provided $19.2 billion for the modernization of electronic
health records [1]. The Health Information Technology for
Economic and Clinical Health (HITECH Act), contained
within the ARRA, also codified into law an executive order
by President Bush from 2004 that created the Office of the
National Coordinator for Health Information Technology
(ONC) as part of the Department of Health and
Human Services, which is charged with ensuring that
all patients have a certified electronic health record
by 2014. In addition, health care providers and hospitals
who adopt a “meaningful” use of EHR will be eligible for
incentive payments [2].
During this period of reform the Substance Abuse
Mental Health Services Administration (SAMHSA), the
agency of the Department of Health and Human Services
(DHHS) responsible for the prevention and treatment of
substance use disorders, has provided support for the
coordination and integration of SUD treatment and
healthcare. SAMHSA lists as core consensus principles in
health reform to “eradicate fragmentation by requiring
coordination and integration of care for physical, mental,
and substance use conditions” and “adopt and fullyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these legislative and policy developments will increase
accessibility to behavioral health services and facilitate the
coordination of care for patients in health care settings
with the goal of improving care for patients in the United
States. Given the under-detection and under-treatment of
SUDs, coordinated care environments, such as practitioners
in health care settings who screen for and treat individuals
who are engaging in risky or problematic substance use,
can increase the detection and treatment of SUDs among
patients who may not otherwise present for specialty SUD
treatment [4].
Why confidentiality laws?
42 CFR Part 2. The federal regulations, 42 CFR Part 2
[5,6], were developed during a time of independent SUD
treatment programs, to increase treatment engagement
and reduce the discrimination associated with SUD treat-
ment. The regulations have since been updated but their
purpose has remained intact: to prevent law enforcement
from using substance abuse treatment patient records as a
means of arresting patients [7]. Congress, wishing to make
substance abuse treatment more accessible stated, “The
conferees wish to stress their conviction that the strictest
adherence to . . . [confidentiality] is absolutely essential to
the success of all drug abuse prevention programs. Every
patient and former patient must be assured that his right
to privacy will be protected. Without that assurance, fear
of public disclosure of drug abuse or of records that will
attach for life will discourage thousands from seeking the
treatment they must have if this tragic national problem is
to be overcome" [8] p.33.
42 CFR Part 2 [5,6] applies confidentiality regulations to
federally-assisted SUD programs, defined as an individual,
entity, or unit within a general medical facility who offers
or provides substance use diagnosis, treatment or referral
to treatment or medical staff in a general medical care
setting “whose primary function is the provision of alcohol
or drug abuse diagnosis, treatment or referral for treat-
ment” [6; 2.11]. To be consistent with the 42 CFR Part 2
language, substance use providers and settings, who meet
the above criteria, will be referred to as “SUD programs”
throughout our discussions of privacy laws in SUD care.
“Patient” refers to “any individual who has applied for or
been given diagnosis or treatment for alcohol or drug abuse
at a federally assisted program and includes any individual
who, after arrest on a criminal charge, is identified as an
alcohol or drug abuser in order to determine that
individual’s eligibility to participate in a program” [6; 2.11].
42 CFR Part 2 stipulates that the “records of the identity,
diagnosis, prognosis, or treatment of any patient which
are maintained in connection with the performance of any
drug abuse prevention function conducted, regulated, or
directly or indirectly assisted by any department or agencyof the United States” [6; 2.1] may not be disclosed to
others unless the patient gives prior written consent
for the release of his/her information. Thus, programs
meeting the 42 CFR Part 2 criteria may not share any
information relating to the patient without specific
patient consent. Patient consent is required for each
disclosure (no blanket waivers of consent are permitted),
and re-disclosure is forbidden unless a provider receives
patient consent.
While the general rule is no disclosure without patient
consent, the confidentiality regulations have boundaries.
Disclosures to medical personnel are allowed without
specific patient authorization for medical emergencies if
there is an immediate threat; however this information
must be documented in the patient’s records. Suspected
child abuse or neglect may be reported, but restrictions
still apply to the original patient records of the SUD
program; in other words a report is allowed but disclosure
that the patient is in a SUD program is not permitted. With
the patient’s consent disclosure is authorized to a qualified
service organization (QSO): This is an organization that
has a written agreement (Qualified Service Organization
Agreement or “QSOA”) with the SUD treatment program,
stating that the QSO will be governed by the confidentiality
regulations, with no disclosure without consent, and will
resist judicial efforts to obtain patient records.
In recent years (2010–2011) SAMSHA set forth two
sets of Frequently Asked Questions (FAQs) to further
clarify how the existing legislation is applicable with
the current technological advances. “Applying the
Substance Abuse Confidentiality Regulations to Health
Information Exchange” and “Applying the Substance
Abuse Confidentiality Regulations 42 CFR Part 2” describe
a variety of issues including the limitations of consent, the
role of HIPPA, and the relationship between 42 CFR part
2 and state laws [9]. These FAQs are intended to clarify
the 42 CFR Part 2 guidelines, however many questions
remain about how to interpret the guidelines in coordinated
care environments and in the context of an ever-changing
digital era. Furthermore, while there has been considerable
improvement in the technology for documenting treatment
and the integration of SUD treatment with medical care,
our current privacy laws regarding substances use disorders
remain largely unchanged.
HIPAA regulations
As years passed, additional legislation was adopted to
further ensure patient privacy. In 1996, the United States
Congress passed the Health Information Portability and
Accountability Act (HIPAA), which contains a privacy rule
that restricts the spread of Protected Health Information
(PHI). HIPAA regulates PHI held by “covered entities”,
such as health plans, health care clearinghouses, and health
care providers. HIPAA was written for direct transfers of
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networks streamlining information [10]. Some view
HIPAA as restricting the necessary transfer of data
and needing improvements to facilitate smoother
communication [10-12] whereas others suggest that
the HIPAA Privacy Rule should be augmented with
new federal regulations [13].
Modifications have been proposed to address some of
the privacy issues with 42 CFR Part 2 and HIPAA. For
example, the Patient Protection Coalition, a group aiming
to reform 42 CFR Part 2, has suggested permitting
disclosures of demographic information, diagnosis,
medications, laboratory results, and current and past
treatment providers to ensure patient safety. Additionally,
they support enhancing patient protections regarding
discrimination based on having received SUD treatment
and strengthening legal ramifications for unauthorized
disclosures of information [14].
Federal privacy laws are further complicated with the
advent of electronic medical records [15]. Federal privacy
laws were written before the development of electronic
medical records, when all records were kept in paper form,
rendering some parts of these laws obsolete and other parts
in opposition to the electronic changeover [16]. Various
groups insist on maintaining the strict protections in 42
CFR Part 2 [17] whereas others argue for a reform of the
current confidentiality protections [18].
Integration of SUD treatment and healthcare
Increasingly, substance use treatment services are being
offered in health care settings at the urging of groups
such as the Institute of Medicine [19]. This shift reflects
the realization that many individuals drinking or using
drugs at risky levels will present for care in mainstream
health care settings rather than specialty SUD programs.
These patients may be in need of SUD treatment but
may be unwilling or unable to seek specialty substance
use care. Integrating “medically harmful substance use”
information into EHRs can improve patient safety and
provide better care to patients [20]. Efforts, such as the
Screening and Brief Intervention and Referral to Treatment
initiative funded by SAHMSA, encourage the assessment
and treatment of substance use disorders in healthcare
settings [21] and have been successful in reducing patients’
alcohol and drug use [22].
The integration of SUD treatment and healthcare
settings can be an effective way of assessing and treating
patients who may not have pursued specialty SUD care
and in providing a greater continuity of care for those
patients who are receiving specialty SUD treatment.
However, combining these services is complicated, in
part due to the greater protections offered to patients in
certain settings with substance use disorders. When
general health care providers assess for and provide abrief intervention in a general health care setting, the
documentation of the pertinent substance use information
does not fall under the SUD confidentiality regulations
[23]. However, if a patient in a federally-funded healthcare
setting is seen or treated by a specialty substance abuse
provider whose primary job responsibility is to assess for
and treat substance use patients, this patient-provider
information does merit protection under the 42 CFR
Part 2 confidentiality regulations. At this point, providers
must document only essential information within the
medical record. As Miller et al. [23] note, “The problem
here is determining what is essential for primary care pro-
viders to know. Primary care providers themselves may
argue that they need to know everything in order to pro-
vide the best care to the patient” (p.294).
There is ambiguity about the documentation of integrated
substance abuse information in healthcare settings, with no
uniform method of recording this material. For instance,
when SUD treatment services were implemented into a
university associated primary care clinic in New Mexico,
Ernst, Miller, and Rollnick [24] reported on the lack
of clarity regarding confidential protections in a primary
care setting. After seeking legal counsel, the authors
decided to adhere to the regulations because “the services
were specific to substance abuse, and psychotherapy was
provided to some patients” [24], p. 3.
The integration of SUD treatment and health care
raises questions about what integration means for
SUD documentation in health care settings. Integration
also highlights possibly discordant regulations regarding
the treatment of SUDs in substance use and health
care settings. If the SUD confidentiality regulations
do not apply to a general medical doctor prescribing
naltrexone in a primary care setting or talking to a
patient about the risks of drinking while pregnant
what is the rationale for the discrepancy in protections? In
Table 1 we highlight the discrepancy between the
documentation of SUD information by SUD in federally
assisted SUD-focused programs versus general medical
providers in non-SUD settings.
Confidentiality protections in current practice
Practitioners ask as we move toward an era where
medications are increasingly being prescribed for SUD,
are the current protections potentially harmful to
patients? Providers of patients who are prescribed
naltrexone, buprenorphine, or methadone may need
this information in order to accurately treat their patients.
While the 42 CFR Part 2 guidelines indicate that patient
information may be disclosed in medical emergency situa-
tions, preventing a potentially fatal drug interaction does
not necessitate a disclosure if there is not an immediate
medical emergency [25]. A study by Walley et al. [26]
found that 59% of the opioid patients on methadone
Table 1 SUD Documentation in specialty and general medical setting
Specialty SUD provider in federally-assisted SUD program Documentation and explanation
- Patient schedules an appointment with a SUD clinic because
he is concerned about his alcohol use.
The SUD counselor documents the details of the patient’s visit in the SUD
clinic notes. These notes are protected by 42 CFR Part 2 and are therefore
not accessible to others outside the program (in particular the patient’s
primary care provider), without a specific release of information from the
patient unless there is a qualifying medical emergency or an established
QSOA exists.
- Patient completes a brief assessment interview and then meets
with his counselor.
- Patient and his counselor discuss the patient’s goals for treatment,
and patient is encouraged to attend weekly SUD sessions. Patient is
not actively withdrawing from alcohol, so counselor decides that
patient does not to attend a detoxification center.
- Patient asks if there are medications to help him deal with cravings, but
counselor indicates he does not have prescription privileges. Patient is
encouraged to ask his primary care provider about the use of naltrexone.
Medical Provider in Emergency Room Documentation
- Patient is asked about his alcohol and drug use as part of a visit to
an emergency room for a traumatic injury. Patient indicates his injury
occurred while intoxicated and voices concern about drinking.
Provider documents the details of the patient’s visit, including the
patient’s SUD diagnosis and history of drinking. This information is not
protected by 42 CFR Part 2 because the provider’s primary function did
not include the provision of substance use services nor did the
interaction take place in an identified substance-focused unit.- Provider (general medical provider) assesses substance use history and
diagnoses the patient with alcohol dependence.
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tions with a potentially harmful interaction with their
MMT. In fact, 19% of the patients were prescribed three or
more medications that could potentially interact with
MMT. Currently, the patient must serve as the inter-
mediary between their SUD and healthcare providers
or sign an authorization of release of information for
each of their particular providers. As a result “failure
to share patient-specific information across providers
promotes uncoordinated and sometimes unsafe care”
[27], p. 716.
Nonetheless, in a recent national survey, adults have
expressed some concerns about the potential for shared
health information. In this survey, 42% of participants
indicated that they would feel uncomfortable if their
private health information was shared with other organi-
zations, even if any identifying information was excluded.
Furthermore, 15% of participants reported that they would
hide information and 33% indicated that they may hide
information from their doctor if he/she shared informa-
tion through an EHR [28]. Patients with substance use
disorders or risky substance use may be more likely to
hide substance use information out of privacy concerns
and fears of stigmatization.
Solving a clinical conundrum: maintaining confidentiality
in a coordinated care environment
In 2010 an article in Alcoholism & Drug Abuse Weekly
[7] asked, “Can electronic medical records and patient
confidentiality coexist?” The answer appears to be “Yes,
but they need to be harmonized.” People involved in this
tuning process will include legislators, judges, attorneys,
and insurance adjusters, but a major place where these
issues will be acted out is in human service programstreating people with SUD. With that in mind, we provide
some suggested actions that staff in SUD treatment
programs can take to cope with these controversies.
Keep context in mind
For all providers and other healthcare personnel, it is
vital to understand the reasons why the confidentiality
laws exist and also why the context is changing. Gaining
an understanding in the principles, laws, and guidelines
is important. Then when the question arises about
protection of confidentiality, ethical principles such as
respect for persons, autonomy, justice, beneficence, and
non-maleficence can be part of the decision-making
process [29]. The federal confidentiality statutes need to be
followed, as well as various guidelines from legislation like
HIPAA and applicable state and municipal regulations.
Guidelines are available from several valuable resources.
CSAT/SAMHSA has developed over 50 written Treatment
Improvement Protocols. These are available online at
http://www.ncbi.nlm.nih.gov/books/NBK14119/ and were
written for staff in a wide variety of SUD treatment
programs. CSAT has also published a number of Technical
Assistance Publications (TAPS), including TAP 13,
Confidentiality of patient records for alcohol and drug
treatment [30]. TIP 40, Clinical guidelines for the use
of buprenorphine in the treatment of opioid addiction,
has specific information on the confidentiality requirements
for physicians who are providing office-based opioid
addiction treatment. The TIP also includes a sample
consent form to release information protected by 42
CFR Part 2 [31]. Additionally the Legal Action Center
(LAC) can be an excellent resource, available online
at http://www.lac.org/. LAC is a non-profit law and
policy organization that seeks to fight discrimination
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records. They provide on-line courses available both in
basic and advanced issues concerning confidentiality,
as well as brochures, sample forms for physicians and
treatment programs, and policy analyses, including a
paper on confidentiality of alcohol and drug records
in the 21st Century.Consider state laws
State laws may institute additional protections on
patients’ privacy, so it is important to remain informed
about state confidential protections. While states may
require additional protections, they may not authorize a
program to disclose information that is protected by 42
CFR Part 2. Thus, state laws may provide additional
protections but they may not undermine the federal
protections.Seek guidance
When a provider approaches an uncomfortable situation
it is wise to seek guidance. Counselors, peers, clinical
supervisors, physicians, and licensed professionals at the
SUD treatment program are essential for support, and
professional associations can be helpful. For example
the NAADAC, the National Association for Addiction
Professionals (http://www.naadac.org/), offers webinar
trainings, one of which is Compliance with Ethical
Standards for Drug, Alcohol and Addictions Counselors.
We stress that the specific guidelines may be changing
constantly as new information emerges. For example, earlier
in this paper we mentioned that in July 2010 CSAT
released a “Frequently Asked Questions” paper (http://
www.samhsa.gov/HealthPrivacy/docs/EHR-FAQs.pdf). The
paper was initially drafted by the LAC. Enos [32] docu-
ments the many points of controversy about this document,
and a month later SAMHSA sponsored a stakeholders
meeting to air different viewpoints and clarify the “FAQs”.
We also emphasize the importance of seeking legal
guidance, which is a vital step in situations where
rules may be changing, and new legal precedents may
be emerging. A treatment counselor is likely to need
both clear and authoritative guidance from a legal
professional.Implement
At the clinic level, update guidelines for your patients,
staff, and referral sources, and if guidelines do not
exist, it may be wise to develop them. Examples of
such guidelines are available from the CSAT TIPS and
TAPS mentioned above, or they may be available locally
or through the single state agency that is responsible for
SUD treatment.Seek feedback
Obtaining feedback from those affected is an obvious
suggestion, but feedback often happens only when
something has gone wrong. Encourage quality assurance
studies to understand what is working and why. Encourage
research to understand how serious specific issues are in
your setting. As an example of the utility of research,
Salomon et al. [33] surveyed psychiatric clinicians
who had recently switched to an electronic health
record system and found the majority opinion was
that open therapeutic communications were not interfered
with. On the other hand, once they were using the
electronic health record system the majority was less
willing to record highly confidential information. In
short, the clinicians indicated that the system worked but
they were more cautious than before about recording
sensitive information.
Keep learning
At the individual level, keep up to date as guidelines
change. A 2009 CSAT TIP entitled Clinical Supervision
and Professional Development of the Substance Abuse
Counselor may be helpful (TIP 52) [21]. At the program
and system levels attend to the needs for training among
those in your system. In addition, as the ethical standards
continue to evolve in substance abuse treatment, it is
essential that providers remain up to date on the latest
ethical guidelines.
Conclusions
This manuscript explored protecting confidentiality in
SUD treatment programs in the light of changes that
have occurred recently in the policies and regulations.
Legislation has been enacted to make SUD treatment
more affordable and accessible to patients in need.
Treatments are increasingly being offered in health care
settings such as primary care clinics, emergency, and
trauma units. Technological development has fostered
the development and proliferation electronic health records
rather than paper charts. In this context we acknowledge
the difficulty of maintaining patient confidentiality versus
sharing vital information with providers in a collaborative
care setting. In this paper the authors provide a summary
of recent legislative and policy changes, the reasons for
confidentiality protections, review the degree that substance
abuse documentation is protected in different environ-
ments, and suggest several directions for maintaining confi-
dentiality while promoting coordination of care. The field
of substance abuse treatment has changed drastically since
the time when the privacy laws were first developed. SUD
treatment is more widely available, provided by a broad
range of health care providers, and is often treated by
medications. The integration of SUD care has reached
patients who may not have otherwise sought treatment.
Manuel et al. Addiction Science & Clinical Practice 2013, 8:13 Page 6 of 7
http://www.ascpjournal.org/content/8/1/13Our paper provides guidance and advice to staff in
SUD treatment programs regarding how to negotiate
confidentiality issues in treatment programs. The issues
are changing, and the ethical principles of good health
care and professional practice will be increasingly
relevant in this time when the field is undergoing significant
change in its clientele, location of services, and its
technology. Until the field stabilizes again it will be
the helping professionals in the human service settings
who make the most important decisions about what is
best for their clientele.
This analysis is limited by several factors that can be
informed through further research. There is a need for
clear ethical analyses that explore the advantages and
drawbacks of topics such as protecting patient confidenti-
ality versus promoting integrated care. It would be helpful
to understand more about the extent of stigmatization of
SUD and whether, over time the stigma has diminished or
increased. This information can inform guidance about the
extent to which confidentiality protections are needed by
those receiving treatment for SUD. Additional research
needs to provide information about what are the most fre-
quently occurring and most troubling ethical confidentiality
and privacy issues facing various actors in SUD treatment
and prevention. In addition we need to know how these
issues are being resolved in the field.
Further there is a need for concerted organizational
attention to resolve an increasingly acrimonious debate
about the need to keep versus revise the federal confi-
dentiality regulations that will soon have been enacted
fully 50 years ago. Our current confidentiality regula-
tions for SUD treatment have not been updated, despite
the number of changes in location and context of care
programs. It may be that federal confidentiality guide-
lines will be rewritten to reflect the changing times, or
like the U.S. Constitution, the field may look to these as
enduring adages that need to be interpreted to provide
more clear guidance to a rapidly evolving field. In either
case, there is a need for the national action to enact
administrative mechanisms that will air the many facets
of the issue and then come to a resolution. With clarity
at the federal level the state and local agencies will be
able to attune their regulations and guidelines so that a
national approach to these issues can develop.
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